EP1929997A1 — Oxcarbazepine formulations
Assigned to Sun Pharmaceutical Industries Ltd · Expires 2008-06-11 · 18y expired
What this patent protects
A pharmaceutical dosage form comprising a mixture of a therapeutically effective amount of oxcarbazepine having median particle size ranging from about 15 µm to about 26 µm and one or more hydrophilic polymers, said mixture being formed by subjecting a suspension comprising said …
USPTO Abstract
A pharmaceutical dosage form comprising a mixture of a therapeutically effective amount of oxcarbazepine having median particle size ranging from about 15 µm to about 26 µm and one or more hydrophilic polymers, said mixture being formed by subjecting a suspension comprising said oxcarbazepine and a hydrophilic polymer in a solvent, to mixing in a homogenizer, optionally removing the solvent and converting the said mixture into a dosage form.
Drugs covered by this patent
- Aptiom (ESLICARBAZEPINE ACETATE) · Sumitomo Pharma Am
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.